Tony S. K. Mok
Lung cancer pioneer whose IPASS trial established EGFR-targeted therapy as first-line treatment; chairs Clinical Oncology at CUHK.
Overview
Tony Mok is Chairman of the Department of Clinical Oncology and Li Shu Fan Professor of Clinical Oncology at The Chinese University of Hong Kong, practising at Prince of Wales Hospital. He led the IPASS trial, which showed that EGFR mutation status predicts benefit from gefitinib over chemotherapy, a landmark in the shift to biomarker-driven lung cancer treatment, and has led numerous subsequent global trials of targeted therapy and immunotherapy in lung cancer.
| Title | Journal | Year |
|---|---|---|
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | New England Journal of Medicine | 2009 |
Pages like this
not linked directly; found by shared links- PersonPhilip Wai Yan Chiu
Shares Prince of Wales Hospital / Chinese University of Hong Kong and the tags leadership, clinician-scientist.
- PersonHidetoshi Hayashi
Shares Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
- PersonAnthony T. C. Chan
Shares Prince of Wales Hospital / Chinese University of Hong Kong and the tags leadership, clinician-scientist.
- PersonMartin Schuler
Shares Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
- PersonCaicun Zhou
Shares Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
- PersonKaren Kelly
Shares Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
- PersonMatthias Guckenberger
Shares Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
- PersonWen-Zhao Zhong
Shares Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.